Short answer: "bioidentical" only means a hormone matches the molecular structure your body makes — it does not mean FDA-approved, safer, or more effective. For women under 60 or within 10 years of menopause, FDA-approved hormone therapy is the most effective treatment for hot flashes and night sweats, with a benefit-risk profile that should be revisited as age, symptoms, and health change.
"Bioidentical" gets used a lot in hormone therapy marketing, and it often implies something it doesn't actually mean. Here's what the term really refers to, what the evidence shows about who benefits most, and how the guidance around HRT has genuinely evolved since the trial that made everyone cautious in the first place.
What "Bioidentical" Actually Means
Bioidentical hormones — most commonly estradiol and progesterone in menopause care — have the same chemical and molecular structure as the hormones your body naturally produces. That's it. The term itself doesn't tell you whether a specific product is FDA-approved, individually compounded, safer, or more effective than alternatives.[1]Bioidentical hormones show up in both categories: there are FDA-approved bioidentical products, and there are custom-compounded bioidentical preparations made for an individual prescription. The regulatory distinction is completely separate from whether something counts as "bioidentical."[1]
Worth knowing upfront:compounded bioidentical preparations aren't FDA-approved, and both the FDA and the American College of Obstetricians and Gynecologists (ACOG) state there's no evidence they're safer or more effective than FDA-approved menopausal hormone therapy.[2] When an FDA-approved option exists, ACOG recommends it over routine use of compounded products — partly because compounded preparations can vary in strength and purity from batch to batch.[2]
What HRT Actually Is
Menopausal hormone therapy (MHT) — the clinical term for what's commonly called HRT — generally means estrogen treatment, with or without a progestogen. Estrogen is the primary treatment; women who still have a uterus typically need a progestogen added alongside systemic estrogen, specifically to reduce endometrial cancer risk.[3] Systemic estrogen — delivered as pills, patches, gels, or sprays — circulates through the bloodstream and addresses body-wide menopausal symptoms. Local vaginal estrogen delivers a much lower dose focused on vaginal tissue, and can be appropriate when vaginal symptoms are the main concern rather than hot flashes or other systemic effects.[3]
What It's Actually Proven to Help With
Hormone therapy is the most effective treatment available for vasomotor symptoms of menopause — hot flashes and night sweats. It also relieves vaginal dryness and pain during sex related to menopausal tissue changes.[3]Systemic therapy helps prevent the accelerated bone loss that happens early in menopause, reducing risk of osteoporosis-related fractures — though it shouldn't be started solely to prevent heart disease, stroke, dementia, or general aging-related changes, since the evidence doesn't support that use.[4]
Why the Benefit-Risk Picture Depends on Timing
This isn't one-size-fits-all. The actual benefit-risk profile depends on the specific hormone, dose, delivery route, how long you're on it, whether a progestogen is included, your age, how long it's been since menopause, your symptoms, and your individual medical history.[4]For women under 60 or within 10 years of menopause onset with no contraindications, the Menopause Society's 2022 position statement describes the benefit-risk ratio as favorable for treating bothersome hot flashes and preventing bone loss.[4]Starting systemic therapy more than 10 years after menopause, or after age 60, generally comes with a less favorable profile — not because it's automatically inappropriate, but because absolute risks of heart disease, stroke, blood clots, and dementia are higher in that group, making individualized assessment more important.[4]
What the WHI Trial Actually Found — and What It Didn't
The Women's Health Initiative trial reshaped this entire field. It found increased risks of coronary heart disease, stroke, pulmonary embolism, and invasive breast cancer with the specific regimen it studied — oral conjugated equine estrogen combined with medroxyprogesterone acetate. It also found lower risks of fractures and colorectal cancer.[5]What's easy to miss is that this result applies to one specific oral regimen, studied in one specific population — not to every type, dose, route, or timing of hormone therapy. That's exactly why current guidance weighs age, timing, formulation, and delivery route individually rather than applying one blanket rule based on a 20-year-old trial of a single regimen.[4]
The Real Risks, Honestly
Combined estrogen-progestin therapy carries a small increase in breast cancer risk; estrogen-only therapy has a different profile. Women with a uterus shouldn't use estrogen alone, since unopposed estrogen raises endometrial cancer risk — this is the core reason progestogen gets added.[3] Both estrogen-only and combined systemic therapy carry a small risk of stroke and blood clots that rises with age and certain health factors — non-oral forms like patches, sprays, and rings may carry less clot risk than oral pills, though the right route is still an individual decision.[3]There's also a small increased risk of gallbladder disease, highest with oral formulations.[3]Systemic therapy generally isn't recommended for women with a history of breast or endometrial cancer, stroke, heart attack, blood clots, or liver disease, and isn't used during pregnancy — a clinician needs to assess your specific contraindications rather than you self-selecting based on symptoms alone.[3] Early or dose-related side effects can include spotting, breast tenderness, bloating, and headaches; persistent or new bleeding should always get evaluated rather than assumed to be routine.[3]
The Guidance Has Genuinely Shifted
The old "lowest dose, shortest time, for everyone" rule that followed the WHI trial isn't the standard anymore. Current Menopause Society guidance emphasizes finding the right dose, duration, formulation, and route for your specific goals, through shared decision-making with periodic reevaluation — longer-term use can be reasonable for documented, persistent symptoms.[4]
The Bottom Line
The honest takeaway isn't "HRT is good" or "HRT is dangerous" — it's that for the right candidate, particularly starting before age 60 or within 10 years of menopause, FDA-approved hormone therapy is a genuinely effective option, with a risk profile that should be revisited periodically as your age, symptoms, and health change.[3]
If you're evaluating hormone therapy, it's worth comparing how different providers handle diagnosis, delivery method options, and whether they prescribe FDA-approved or compounded products.
Sources
- Menopause — U.S. Food and Drug Administration fda.gov
- Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6 — American College of Obstetricians and Gynecologists / Obstetrics & Gynecology pubmed.ncbi.nlm.nih.gov
- Hormone Therapy for Menopause — American College of Obstetricians and Gynecologists acog.org
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society — The Menopause Society / Menopause pubmed.ncbi.nlm.nih.gov
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial — Women's Health Initiative / JAMA pubmed.ncbi.nlm.nih.gov
Frequently Asked Questions
Does "bioidentical" mean a hormone is FDA-approved?
No — bioidentical only describes molecular structure. Both FDA-approved products and non-approved compounded preparations can be bioidentical; the terms describe two different things.[1]
Is compounded bioidentical HRT safer than FDA-approved HRT?
No — the FDA and ACOG both state there's no evidence compounded bioidentical hormones are safer or more effective than FDA-approved options, and ACOG recommends the FDA-approved option when one is available.[2]
Does the WHI trial mean all hormone therapy is risky?
No — WHI studied one specific oral regimen in one population. Current guidance evaluates risk based on your specific age, timing, formulation, and route rather than applying that single trial's findings universally.[4]
Why do I need progesterone if I'm only treating hot flashes?
If you have a uterus, progestogen is added alongside estrogen specifically to protect against endometrial cancer — estrogen alone raises that risk in women who haven't had a hysterectomy.[3]